MCRB Seres Therapeutics, Inc.
Seres Therapeutics, Inc. (MCRB) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $1.34 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -19.4% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.
Sector
Healthcare
Industry
Biotechnology